沃森生物：子公司收到冻干带状疱疹病毒mRNA疫苗《药物临床试验批准通知书》

Core Viewpoint - Watson Bio announced that its subsidiaries, in collaboration with Fudan University and Shanghai Blue Magpie Biopharmaceutical Co., Ltd., have received approval from the National Medical Products Administration for clinical trials of a lyophilized varicella-zoster virus mRNA vaccine [1] Group 1 - The clinical trial approval notification was issued under the registration categories of preventive biological products [1] - The approval was based on compliance with the Drug Administration Law and Vaccine Administration Law of the People's Republic of China [1] - The application for the clinical trial was accepted on September 18, 2025, and the vaccine meets the requirements for drug registration [1]